• See Also
  1. Phosphodiesterase Inhibitors in COPD
  2. COPD Management
  • Indications
  1. Severe, refractory COPD with Chronic Bronchitis and frequent exacerbations
  • Mechanism
  1. Combined PDE3 and PDE4 Inhibitor
  2. Increases lung intracellular cAMP
  3. Bronchodilates and reduces airway inflammation
  • Medications
  1. Ensifentrine Inhalation aqueous suspension: 3 mg/2.5 mL (unit-dose ampules)
  • Dosing
  1. Shake Ensifentrine ampule before nebulizing (solution may appear cloudy and yellow)
  2. Nebulize 3 mg (one ampule) twice daily
  • Adverse Effects
  1. Uncommon adverse effects
  2. Paradoxical bronchospasm
  3. Suicidality
  4. Hypertension
  5. Diarrhea
  6. Urinary Tract Infections
  7. Back Pain
  • Safety
  1. Unknown safety in pregnancy
  2. Unknown safety in Lactation
  • Efficacy
  1. Efficacy data is limited as of 2024
  2. Very expensive as of 2024 (approaches $3000/month)
  • Resources
  1. Ensifentrine (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e6433c98-41a0-4f99-8f7f-d0e9db6e3f40
  • References
  1. (2024) Presc Lett 31(9): 51